Python-Inspired Weight Loss: New Appetite Suppressant Found in Snake Metabolites

Beyond Ozempic: How Python Metabolism Could Inspire the Next Generation of Weight Loss Drugs

The current landscape of weight-loss medication is, to put it mildly, fraught with secrecy. Reports abound – anecdotal accounts on platforms like Reddit and the New York Post detail patients quietly attributing their success to GLP-1 receptor agonists like Ozempic and Zepbound, rather than acknowledging the effort involved. But researchers are looking beyond these established pharmaceuticals, seeking inspiration from an unexpected source: the extreme metabolic capabilities of Burmese pythons. A recent study, published in Nature Metabolism, identifies a metabolite found in python blood that could offer a novel approach to appetite suppression, potentially with fewer side effects than current GLP-1 drugs.

The Python’s Secret: Para-Tyramine-O-Sulfate (pTOS)

The research, a collaboration between Stanford University, Baylor University, and the University of Colorado Boulder, began with a quest to understand how Burmese pythons can survive for months – even over a year – between meals. These snakes consume massive prey, and the team hypothesized that unique chemical signals must be at play to regulate their metabolism during these extended periods of fasting. What they discovered was para-tyramine-O-sulfate (pTOS), a metabolite that spikes dramatically in python blood after a large meal. Interestingly, pTOS is also produced, albeit in much smaller quantities, in humans after eating.

Researchers fed meals equivalent to 25% of their body weight to younger Burmese pythons (weighing between 1.5 and 2.5 kilograms). This triggered a surge in at least 208 unique metabolites, with pTOS concentrations increasing over a thousandfold. “If we truly want to understand metabolism,” explained study coauthor Jonathan Long of Stanford’s Wu Tsai Neurosciences Institute in a statement, “we need to go beyond looking at mice and people and look at the greatest metabolic extremes nature has to offer.”

How pTOS Works: A Direct Line to the Hypothalamus

Initial tests on laboratory mice revealed that administering pTOS at levels comparable to those observed in pythons didn’t affect energy expenditure, beta cell proliferation, or organ size. Instead, pTOS demonstrably regulated appetite and feeding behavior. This suggests a targeted appetite-suppressant effect without the undesirable side effects sometimes associated with GLP-1 receptor agonists. As Leslie Leinwand, the study’s senior author from CU Boulder, put it, “We’ve basically discovered an appetite suppressant that works in mice without some of the side-effects that GLP-1 drugs have.”

Further investigation revealed that pTOS acts directly on the hypothalamus, a region of the brain crucial for regulating hunger, thirst, and other physiological drives. This is a key distinction from GLP-1 agonists, which exert their effects on multiple organs, including the pancreas and stomach, as noted in research published in International Journal of Molecular Sciences. The more focused action of pTOS could explain the absence of some of the gastrointestinal issues reported by users of GLP-1 medications.

The Gut-Liver Connection and Human Production of pTOS

The team also determined that pTOS is created through the breakdown of tyrosine, a common amino acid found in protein, by bacteria in the gut and liver. While mice don’t naturally produce pTOS, analysis of human urine samples confirmed its presence in humans, particularly after consuming a large meal. This suggests a potential pathway for harnessing the appetite-suppressing effects of pTOS in humans, perhaps through dietary interventions or targeted modulation of gut bacteria.

GLP-1 Receptor Agonists: A Brief Overview

To understand the potential significance of pTOS, it’s helpful to review how GLP-1 receptor agonists work. According to information from Wikipedia, these medications activate the GLP-1 receptor, leading to reduced blood sugar, decreased appetite, and reduced energy intake. Originally developed for type 2 diabetes, some GLP-1 agonists have now been approved for obesity treatment. They mimic the action of the naturally occurring GLP-1 hormone, released in the small intestine, which inhibits glucagon release and stimulates insulin secretion. However, GLP-1 agonists can have side effects, including nausea, vomiting, and diarrhea.

Beyond the Python: Exploring Other Extreme Metabolisms

The researchers aren’t stopping with pTOS. They are continuing to investigate the other metabolites that spiked in the pythons’ blood after feeding, some of which increased by as much as 500% to 800% above baseline levels. This approach builds on a long history of deriving medical breakthroughs from animal sources. Snake venom, for example, has been the basis for developing medications for blood pressure and blood clots. Even GLP-1s themselves were reportedly inspired by a hormone found in the venom of the Gila monster.

“We’re excited to learn from these snakes and other ‘extreme’ animals to inspire future discoveries,” Long said. “Obviously, we are not snakes. But maybe by studying these animals People can identify molecules or metabolic pathways that also affect human metabolism.”

What Comes Next: From Lab to Potential Medication

The discovery of pTOS is still in its early stages. The next steps involve further research to fully understand its mechanism of action in humans, assess its safety and efficacy, and explore potential delivery methods. This will likely involve clinical trials to determine the optimal dosage and identify any potential side effects. Researchers will also need to investigate how pTOS interacts with other medications and dietary factors. The team is also exploring ways to enhance pTOS production in the gut, potentially through prebiotic or probiotic interventions. The goal is to develop a safe and effective weight-loss medication inspired by the remarkable metabolic adaptations of the Burmese python.